Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease

被引:0
作者
Laurent Peyrin-Biroulet
Edouard Louis
Edward V. Loftus
Ana Lacerda
Qian Zhou
Yuri Sanchez Gonzalez
Subrata Ghosh
机构
[1] Nancy University Hospital,Department of Gastroenterology
[2] Université de Lorraine,undefined
[3] University Hospital CHU of Liège,undefined
[4] Mayo Clinic College of Medicine,undefined
[5] AbbVie Inc.,undefined
[6] University of Birmingham,undefined
来源
Advances in Therapy | 2021年 / 38卷
关键词
CELEST; European Quality of Life-5 Dimensions Visual Analog Scale; Inflammatory Bowel Disease Questionnaire; Janus kinase 1; Quality of life; Upadacitinib; Work Productivity and Activity Impairment Questionnaire;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2339 / 2352
页数:13
相关论文
共 106 条
[1]  
Roda G(2020)Crohn's disease Nat Rev Dis Prim 6 22-517
[2]  
Chien Ng S(2018)ACG clinical guideline: management of Crohn's disease in adults Am J Gastroenterol 113 481-1755
[3]  
Kotze PG(2017)Crohn's disease Lancet 389 1741-25
[4]  
Lichtenstein GR(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management J Crohns Colitis 11 3-2778
[5]  
Loftus EV(2018)Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Lancet 390 2769-2288
[6]  
Isaacs KL(2015)Assessing quality of life in Crohn's disease: development and validation of the Crohn's Life Impact Questionnaire (CLIQ) Qual Life Res 24 2279-861
[7]  
Regueiro MD(2011)A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version Value Health 14 859-596
[8]  
Gerson LB(2017)Validation of the inflammatory bowel disease disability index in a population-based cohort Gut 66 588-995
[9]  
Sands BE(2011)Review article: loss of response to anti-TNF treatments in Crohn's disease Aliment Pharmacol Ther 33 987-684
[10]  
Torres J(2011)Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review Am J Gastroenterol 106 674-63